Evidence map›Paper›PMID 42466814›Full record

Observational studyActa psychiatrica Scandinavica2026

Patients With Atypical Symptoms of Depression Respond Better to Lithium Augmentation Than Patients Without Atypical Symptoms.

Hannah Buchbauer, Mazda Adli, Peter Schlattmann, Maximilian Berger, Tom Bschor, Thomas Stamm, Joachim Behr, Roland Ricken, Pichit Buspavanich

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Acta psychiatrica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hannah BuchbauerDepartment of Psychiatry and Neuroscience, Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID https://orcid.org/0009-0006-8082-3753
Mazda AdliDepartment of Psychiatry and Neuroscience, Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-0993-5617
Peter SchlattmannDepartment of Statistics, Informatics and Data Science, Jena University Hospital, Jena, Germany.ORCID https://orcid.org/0000-0001-7420-7707
Maximilian BergerDepartment of Psychiatry and Neuroscience, Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0003-2961-0251
Tom BschorDepartment of Psychiatry and Psychotherapy, Technical University of Dresden Medical School, Dresden, Germany.
Thomas StammDepartment of Psychiatry and Neuroscience, Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Joachim BehrDepartment of Psychiatry, Psychotherapy and Psychosomatics, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany.
Roland RickenDepartment of Psychiatry and Neuroscience, Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Pichit BuspavanichDepartment of Psychiatry and Neuroscience, Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-4545-2575

Funding

Lundbeck GmbHMood Disorders Research Group
6 · The paper itself

Abstract

introductionUnderstanding the differences in treatment response between subtypes of major depressive disorder (MDD) may help to prevent lengthy trial-and-error processes by identifying effective treatment options. The aim of the study was to investigate the impact of atypical features of MDD (MDD-A) on the response to lithium augmentation (LA).

methodsIn a multicenter prospective cohort study, response to LA was compared between patients with atypical symptoms of MDD (MDD-A, n = 24) versus patients without atypical symptoms (MDD-nA; n = 94) using a Cox regression analysis.

resultsA total of 62.5% of patients with MDD-A and 36.2% of patients with MDD-nA responded to LA. Analysis adjusted for age, sex, sufficient lithium serum concentration, and symptom severity at baseline showed a significantly higher probability of patients with atypical symptoms to respond to LA (HR 2.20, p = 0.02).

conclusionThis is the first study investigating lithium-response in patients with MDD-A. The MDD-A subtype may help to predict response to LA.

trial registrationEudraCT number: 2008-004182-26; ClinicalTrials.gov identifier: DRKS00026205.

Indexed as

Antidepressive AgentsLithium CompoundsMajor Depressive DisorderAdultDrug Therapy, CombinationFemaleHumansMaleMiddle AgedProspective StudiesTreatment Effect HeterogeneityAntidepressive AgentsLithium Compoundsantidepressant therapyatypical featuresatypicalitymajor depressive disorderresponsetreatment resistant depression

Identifiers

PMID42466814
PMCPMC13630508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.